Michael Millward

6.9k total citations · 1 hit paper
43 papers, 2.9k citations indexed

About

Michael Millward is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Millward has authored 43 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Millward's work include Melanoma and MAPK Pathways (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Lung Cancer Research Studies (7 papers). Michael Millward is often cited by papers focused on Melanoma and MAPK Pathways (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Lung Cancer Research Studies (7 papers). Michael Millward collaborates with scholars based in Australia, United States and Germany. Michael Millward's co-authors include A Płużańska, Joachim von Pawel, E. Kaukel, Rodryg Ramlau, Frank V. Fossella, K. Mattson, Chandra P. Belani, Vera Gorbounova, Aleksandra Szczęsna and Jose R. Pereira and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Michael Millward

43 papers receiving 2.9k citations

Hit Papers

Randomized, Multinational, Phase III Study of Docetaxel P... 2003 2026 2010 2018 2003 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
    2003 763 citations Frank V. Fossella, Jose R. Pereira et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Millward Australia 25 1.7k 1.1k 1.1k 331 331 43 2.9k
Irene Braña Spain 26 1.3k 0.7× 601 0.5× 1.3k 1.1× 203 0.6× 359 1.1× 137 2.6k
V.A. Miller United States 22 2.1k 1.2× 1.6k 1.4× 924 0.8× 323 1.0× 508 1.5× 83 3.0k
Paul Frankel United States 34 1.9k 1.1× 967 0.8× 1.8k 1.5× 365 1.1× 658 2.0× 214 4.1k
Y Ariyoshi Japan 31 3.2k 1.8× 2.8k 2.5× 2.0k 1.7× 416 1.3× 427 1.3× 127 5.5k
Anna Spreafico Canada 31 2.3k 1.3× 1.2k 1.0× 1.2k 1.1× 377 1.1× 591 1.8× 229 3.8k
Christina S. Baik United States 27 2.1k 1.2× 1.8k 1.6× 1.3k 1.1× 239 0.7× 685 2.1× 116 3.5k
Drew Rasco United States 33 2.4k 1.4× 980 0.9× 1.7k 1.5× 293 0.9× 516 1.6× 192 4.1k
Albiruni R. Abdul Razak Canada 29 2.0k 1.1× 1.1k 1.0× 1.1k 1.0× 368 1.1× 571 1.7× 96 3.5k
Andréa Varga France 33 3.0k 1.7× 1.2k 1.1× 1.2k 1.1× 911 2.8× 547 1.7× 107 4.6k
Marta Guix Spain 17 1.4k 0.8× 714 0.6× 1.1k 1.0× 348 1.1× 599 1.8× 43 2.5k

Countries citing papers authored by Michael Millward

Since Specialization
Citations

This map shows the geographic impact of Michael Millward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Millward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Millward more than expected).

Fields of papers citing papers by Michael Millward

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Millward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Millward. The network helps show where Michael Millward may publish in the future.

Co-authorship network of co-authors of Michael Millward

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Millward. A scholar is included among the top collaborators of Michael Millward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Millward. Michael Millward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hauschild, Axel, Paolo A. Ascierto, Dirk Schadendorf, et al.. (2020). Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer. 125. 114–120. 50 indexed citations
2.
Meehan, Katie, Michelle R. Pereira, Connull Leslie, et al.. (2020). A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Scientific Reports. 10(1). 6083–6083. 42 indexed citations
3.
Gray, Elin S., Michelle R. Pereira, Leslie Calapre, et al.. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics. 21(3). 418–426. 18 indexed citations
4.
Dunkel, Ying, Anna Reid, Jason Ear, et al.. (2018). Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. Scientific Reports. 8(1). 18036–18036. 6 indexed citations
5.
Fuller, Kathryn A., Wendy N. Erber, Katie Meehan, et al.. (2015). Mutational Analysis of BRAF Inhibitor–Associated Squamoproliferative Lesions. Journal of Molecular Diagnostics. 17(6). 644–651. 7 indexed citations
6.
Grob, Jean‐Jacques, Mayur M. Amonkar, Salvador Martín‐Algarra, et al.. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology. 25(7). 1428–1436. 37 indexed citations
7.
Reid, Anna, James Freeman, Michael Millward, Mel Ziman, & Elin S. Gray. (2014). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry. 48(15). 999–1002. 84 indexed citations
8.
Gray, Elin S., et al.. (2013). Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology. 3. 54–54. 26 indexed citations
9.
Amanuel, Benhur, Fabienne Grieu, Jasreen Kular, Michael Millward, & Barry Iacopetta. (2012). Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology. 44(4). 357–359. 45 indexed citations
10.
Harvey, Nathan T., Michael Millward, & Benjamin A. Wood. (2012). Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition. American Journal of Dermatopathology. 34(8). 822–826. 27 indexed citations
11.
12.
Francis, Roslyn J., Michael Byrne, J Bouček, et al.. (2007). Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans. Journal of Nuclear Medicine. 48(9). 1449–1458. 151 indexed citations
13.
Millward, Michael. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma. Journal of Clinical Oncology. 24. 7 indexed citations
14.
Belani, Chandra P., Jose R. Pereira, Joachim von Pawel, et al.. (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life. Lung Cancer. 53(2). 231–239. 48 indexed citations
15.
Millward, Michael, Anthony M. Joshua, Richard Kefford, et al.. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs. 23(3). 253–256. 26 indexed citations
16.
17.
Millward, Michael, Michael Boyer, M. Lehnert, et al.. (2003). Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology. 14(3). 449–454. 90 indexed citations
18.
Millward, Michael, Richard A. Fisher, Sandro Porceddu, et al.. (2001). Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer. Lung Cancer. 31(1). 73–82. 4 indexed citations
19.
Tebbutt, Niall C., Danny Rischin, Michael Quinn, et al.. (1998). A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology. 38(1). 87–90. 2 indexed citations
20.
Shapiro, Jeremy, Michael Millward, Danny Rischin, et al.. (1996). Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. Gynecologic Oncology. 63(1). 89–93. 223 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irene Braña Breakdown of academic impact, for papers by V.A. Miller Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by Y Ariyoshi Breakdown of academic impact, for papers by Anna Spreafico Breakdown of academic impact, for papers by Christina S. Baik Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Marta Guix
Rankless by CCL
2026